Clinical Trial

A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

Study acronym: PREDICT-HP
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 9, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Up to 150 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-04-09; most recent amendment 2026-04-06.
Status change: Recruiting → Active, Not Recruiting 2025-05-09
Trial Details
NCT Number NCT04844359
Lead Sponsor National Jewish Health
Collaborators: University of California, Davis, Mayo Clinic, University of Chicago, University of Texas Southwestern Medical Center, University of Arizona, University of Utah
Conditions Hypersensitivity Pneumonitis
Enrollment 137 participants
Start Date 2021-01-06
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-09